Analyst Dennis Kennedy from LifeSci Capital maintained a Buy rating on Perspective Therapeutics (CATX – Research Report) and keeping the price target at $17.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Dennis Kennedy’s rating is based on several strategic developments and promising data from Perspective Therapeutics. The company has successfully aligned with the FDA to proceed with enrolling patients in Cohort 3 of their Phase 1/2a study, which investigates a higher dose of their Pb212-based SSTR2 targeting therapy for neuroendocrine tumors. This higher dose of 6.0 mCi is expected to potentially improve the overall response rate beyond the 57% observed at the 5.0 mCi level, indicating a strong therapeutic potential.
Additionally, the dosimetry data presented at SNMMI supports the safety of this higher dosing, as the FDA has shown comfort with the kidney absorbed dose levels, which exceed historical limits. Furthermore, Perspective’s diagnostic agent, PSV377, has shown valuable preclinical and clinical evidence for imaging FAP positive tumors, enhancing patient selection for ongoing studies. These factors collectively contribute to Kennedy’s optimistic outlook and Buy rating for Perspective Therapeutics.
According to TipRanks, Kennedy is a 3-star analyst with an average return of 26.3% and a 100.00% success rate.